Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

CiPA used to validate Axol's iPSC-derived ventricular cardiomyocytes for cardiac safety testing

June 8, 2022

Novel NPR-C activator for the treatment of cardiovascular disease

June 2, 2022

Anti-NOTCH3 treatment reverses experimental pulmonary arterial hypertension

June 1, 2022

Arena Pharmaceuticals synthesizes new 5-HT2A receptor antagonists

May 27, 2022

Idorsia Pharmaceuticals patents new LGALS3 inhibitors

May 24, 2022

A novel gene therapy for heart failure treatment based on DWORF micropeptide

May 23, 2022

AAV9-cTnT-GSLA01, a gene therapy to treat LMNA dilated cardiomyopathy

May 18, 2022

Tripartite interactions between nervous system, immune cells and plaques drive atherosclerosis

May 3, 2022

Serine/threonine-protein kinase Pim-1 inhibitors identified at Japan Tobacco

May 3, 2022

Bristol Myers Squibb describes new FPR1/2 agonists

May 2, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...